

PreveCeutical Medical Inc.

14:20 29 Oct 2019

PreveCeutical Medical says it is moving towards proof of concept with its blue scorpion venom research

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) revealed it has advanced its scorpion venom-derived research and development (R&D) program toward proof of concept studies.

The health sciences group, which is developing innovative preventive therapies using organic and nature identical products, noted that venom from the Caribbean blue scorpion has been shown to impact aggressive cancers, such as in the brain.

READ: PreveCeutical completes efficacy screening of small interfering RNA-based therapy for type 2 diabetes

The firm said its research partner, via work, has whittled down four peptides to two which show the most potential for further development as therapeutic agents in the management of certain brain cancers.

The two peptides were "able to inhibit the activity of the target protein", which resulted in an obvious slowing of invasion, particularly in cancer cells, the company added.

They also displayed modest suppression of an important cancer cell marker, which has a role in promoting cancer spread/metastasis and is also associated with drug and immune resistance in brain cancer, the Vancouver-based firm said.

Accelerating the process

PreveCeutical said it was now "accelerating the process of evaluating options on how best to progress the two lead peptide drug candidates", which may include partnering to speed up pre-clinical evaluation.

"The pre-clinical outcomes, along with the company's IP coverage, would have the potential to demonstrate proof of concept and enable the company to further extend dialogue with pharma R & D / biotech companies active in the therapeutic neuro-oncology space," it noted.

"We are indeed quite excited to have accomplished further strides towards proof of concept for these innovative Nature Identical peptide therapeutics for application into the neuro-oncology therapeutic area and look forward to progressing them through proof of concept studies," said PreveCeutical's president and chief science officer Dr Mak Jawadekar.


Shares surged 20% in Toronto to C\$0.030 each.

Contact the author at giles@proactiveinvestors.com

Price: 0.015

Market Cap: \$5.95 m

1 Year Share Price Graph



Share Information

Code: PREV

Listing: CSE

52 week High Low
0.075 0.01

Sector: Medical technology & services

Website: preveceutical.com

Company Synopsis:

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilising organic and nature identical products.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).